Innovation for Health - 15-16 April 2021
Contact
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare

Tim Knotnerus

CEO, AgomAb Therapeutics

 

AgomAb Therapeutics is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. In April 2019, a 21 million euros financing round was raised. Prior to AgomAb Therapeutics, Tim was VP Corporate Development at AM-Pharma where he was responsible for Corporate and Business Development of the company. In that capacity he co-led the $600M option-to-acquisition deal between Pfizer and AM-Pharma. Prior to that, Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies, where he was instrumental in the financing and support of various portfolio companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).
Jan van de Winkel
Genmab
Eline Vrijland-van Beest
Hybridize Therapeutics

Carmen van Vilsteren
Topsector Life Science & Health

Tim Van Hauwermeiren 
argenx

Antoon van Oosterhout
Imyse SA
Willem Mulder
TU/E
Jolanda M. de Vries
Radboudumc
Yvette van Kooyk
Amsterdam UMC
Ronald Plasterk
Frame Cancer Therapeutics
Paul WG Elbers
Amsterdam UMC
Prof. Dr. Ing. Ron A.M. Fouchier
Erasmus MC
Sponsors & Partners 2021
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Main Virtual Conference sponsor
Silver sponsor
Programme Sponsor AI
Award sponsor
AXON Lawyers
Powered by
Hyphen Projects
© 2020 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.
By continuing to use this site, you consent to our use of cookies. For more information, read: www.innovationforhealth.nl/privacy-policy